Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influenza Vaccine Challenge in MDD
NCT02415166Terminated
- Start
- Jul 2015
- Primary completion
- Mar 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial of ARCT-2138 in influenza (4 arms). Primary endpoint: Titer of Influenza Antibodies at 1 month. Started Jul 2015; status: terminated.
02
Drugs
ARCT-2138
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02415166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02415166.